CL2018001281A1 - Bloqueador del canal de sodio. - Google Patents

Bloqueador del canal de sodio.

Info

Publication number
CL2018001281A1
CL2018001281A1 CL2018001281A CL2018001281A CL2018001281A1 CL 2018001281 A1 CL2018001281 A1 CL 2018001281A1 CL 2018001281 A CL2018001281 A CL 2018001281A CL 2018001281 A CL2018001281 A CL 2018001281A CL 2018001281 A1 CL2018001281 A1 CL 2018001281A1
Authority
CL
Chile
Prior art keywords
sodium channel
channel blocker
present
prevention
pharmaceutically acceptable
Prior art date
Application number
CL2018001281A
Other languages
English (en)
Inventor
Lee Hyung-Geun
Kim Il-Hwan
JUNG Myunggi
Shin Kim Hyo
Ho Lee Chun
Ah Jun Sun
Sung YOON Ji
Kim Sung-Young
Original Assignee
Dae Woong Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dae Woong Pharma filed Critical Dae Woong Pharma
Publication of CL2018001281A1 publication Critical patent/CL2018001281A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/50—Nitrogen atoms bound to hetero atoms
    • C07D277/52—Nitrogen atoms bound to hetero atoms to sulfur atoms, e.g. sulfonamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Pyridine Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un compuesto representado por la Fórmula Química, o una sal farmacéuticamente aceptable del mismo. El compuesto según la presente invención puede usarse de manera útil para la prevención o el tratamiento de enfermedades relacionadas con bloqueantes de canales de sodio.
CL2018001281A 2015-11-13 2018-05-10 Bloqueador del canal de sodio. CL2018001281A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20150159637 2015-11-13

Publications (1)

Publication Number Publication Date
CL2018001281A1 true CL2018001281A1 (es) 2018-08-31

Family

ID=58695815

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2018001281A CL2018001281A1 (es) 2015-11-13 2018-05-10 Bloqueador del canal de sodio.

Country Status (29)

Country Link
US (1) US10227338B2 (es)
EP (1) EP3375782B1 (es)
JP (1) JP6559894B2 (es)
KR (1) KR102245930B1 (es)
CN (1) CN108349963B (es)
AU (1) AU2016351526B2 (es)
BR (1) BR112018009754B1 (es)
CA (1) CA3003119C (es)
CL (1) CL2018001281A1 (es)
CO (1) CO2018005064A2 (es)
EC (1) ECSP18038014A (es)
ES (1) ES2821962T3 (es)
HR (1) HRP20201695T1 (es)
HU (1) HUE052569T2 (es)
MA (1) MA43231B1 (es)
MX (1) MX376469B (es)
MY (1) MY194015A (es)
NZ (1) NZ742069A (es)
PE (1) PE20181301A1 (es)
PH (1) PH12018500999A1 (es)
PL (1) PL3375782T3 (es)
PT (1) PT3375782T (es)
RS (1) RS60927B1 (es)
RU (1) RU2705578C1 (es)
SA (1) SA518391540B1 (es)
SG (1) SG11201803867TA (es)
SI (1) SI3375782T1 (es)
TN (1) TN2018000157A1 (es)
WO (1) WO2017082688A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2017347549A1 (en) * 2016-10-17 2019-05-02 Genentech, Inc. Therapeutic compounds and methods of use thereof
TW202003490A (zh) * 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
WO2020052509A1 (zh) * 2018-09-10 2020-03-19 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途
CN112759559B (zh) * 2019-11-06 2022-08-12 成都康弘药业集团股份有限公司 作为钠通道阻滞剂的磺酰胺类化合物及其用途

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591761A (en) * 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5464853A (en) 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
PT1369419E (pt) * 2001-03-12 2007-08-16 Ono Pharmaceutical Co Composto de n-fenilarilsulfonamida, fármaco contendo o composto como ingrediente activo, produtos intermédios para a produção do composto e processos para a produção do composto
JP2006290791A (ja) * 2005-04-11 2006-10-26 Astellas Pharma Inc アゾール置換スルホニルベンゼン誘導体
WO2006125616A2 (en) * 2005-05-25 2006-11-30 Ingenium Pharmaceuticals Ag Pyrimidine-based cdk inhibitors for treating pain
CA2652669A1 (en) 2006-06-09 2007-12-21 Merck & Co., Inc. Benzazepinones as sodium channel blockers
CA2695613A1 (en) * 2006-12-19 2008-06-26 Pharmos Corporation Sulfonamide derivatives with therapeutic indications
SA08290245B1 (ar) 2007-04-23 2012-02-12 استرازينيكا ايه بي مشتقات كربو كساميد جديدة من -n (8-اريل رباعي هيدرو نفثالين غير متجانس- 2- يل) أو -n (5-اريل كرومان غير متجانس -3-يل) لعلاج الألم
JP2008290791A (ja) * 2007-05-22 2008-12-04 Funai Electric Co Ltd 画像形成装置
US8124610B2 (en) * 2007-07-13 2012-02-28 Icagen Inc. Sodium channel inhibitors
PE20120008A1 (es) * 2009-01-12 2012-01-24 Icagen Inc Derivados de fenoxi bencenosulfonamida
JP2013532184A (ja) * 2010-07-12 2013-08-15 ファイザー・リミテッド 電位開口型ナトリウムチャネル阻害剤として有用なｎ−スルホニルベンズアミド誘導体
JP6014155B2 (ja) * 2011-10-31 2016-10-25 ゼノン・ファーマシューティカルズ・インコーポレイテッドＸｅｎｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． ビアリールエーテルスルホンアミドおよび治療剤としてのそれらの使用
US9012443B2 (en) 2011-12-07 2015-04-21 Amgen Inc. Bicyclic aryl and heteroaryl sodium channel inhibitors
WO2013088315A1 (en) 2011-12-15 2013-06-20 Pfizer Limited Sulfonamide derivatives
WO2013093688A1 (en) 2011-12-19 2013-06-27 Pfizer Limited Sulfonamide derivatives and use thereof as vgsc inhibitors
SG11201408284VA (en) 2012-05-22 2015-02-27 Xenon Pharmaceuticals Inc N-substituted benzamides and their use in the treatment of pain
ES2798138T3 (es) * 2012-10-15 2020-12-09 Dae Woong Pharma Bloqueadores de los canales de sodio, método de preparación de los mismos y uso de los mismos
US20170145003A1 (en) * 2014-02-27 2017-05-25 Mark G. DeGiacomo Heterocyclic inhibitors of the sodium channel

Also Published As

Publication number Publication date
CA3003119C (en) 2019-10-22
WO2017082688A1 (ko) 2017-05-18
HUE052569T2 (hu) 2021-05-28
JP2018533606A (ja) 2018-11-15
BR112018009754A2 (pt) 2018-11-06
MX2018005940A (es) 2018-08-14
AU2016351526A1 (en) 2018-05-17
PL3375782T3 (pl) 2021-02-22
CO2018005064A2 (es) 2018-06-20
EP3375782B1 (en) 2020-07-29
BR112018009754B1 (pt) 2024-01-23
HRP20201695T1 (hr) 2020-12-25
CA3003119A1 (en) 2017-05-18
US10227338B2 (en) 2019-03-12
NZ742069A (en) 2019-08-30
AU2016351526B2 (en) 2019-02-21
SA518391540B1 (ar) 2021-04-06
BR112018009754A8 (pt) 2019-02-26
SG11201803867TA (en) 2018-06-28
TN2018000157A1 (en) 2019-10-04
CN108349963A (zh) 2018-07-31
US20180346459A1 (en) 2018-12-06
KR20170056461A (ko) 2017-05-23
JP6559894B2 (ja) 2019-08-14
EP3375782A4 (en) 2019-05-15
EP3375782A1 (en) 2018-09-19
ECSP18038014A (es) 2018-05-31
ES2821962T3 (es) 2021-04-28
KR102245930B1 (ko) 2021-04-29
MX376469B (es) 2025-03-07
PT3375782T (pt) 2020-08-05
HK1251229A1 (zh) 2019-01-25
RU2705578C1 (ru) 2019-11-08
MA43231B1 (fr) 2020-08-31
RS60927B1 (sr) 2020-11-30
MY194015A (en) 2022-11-08
PE20181301A1 (es) 2018-08-09
PH12018500999A1 (en) 2019-01-28
CN108349963B (zh) 2021-03-30
SI3375782T1 (sl) 2020-10-30

Similar Documents

Publication Publication Date Title
CO2020014586A2 (es) Compuestos
CR20150078A (es) Análogos de piridazina 1,4-disustituida y métodos para el tratamiento de condiciones relacionadas con la deficiencia de smn
CO2019004034A2 (es) Compuesto de piridina
MX2018009175A (es) Agonista fxr derivado de esteroides.
ES2721001T3 (es) Derivado de isoindolina, y composiciones y métodos para tratar una enfermedad neurodegenerativa
CO2018000589A2 (es) Oxiesteroles y composiciones farmacéuticas que los contienen
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
MX380394B (es) Compuesto novedoso de bifenilo o una sal del mismo.
CL2013000713A1 (es) Compuestos pirazin-2-cabonil-imino-1,3,8-triaza-espiro-[4.5]-decan-sustituidos, bloqueadores del canal de sodio epitelial (enac); composicion farmaceutica que los incluye; metodo de prevencion o tratamiento; y su uso para tratar una enfermedad o condicion mediada por el bloqueo del canal de sodio epitelial.
DOP2015000201A (es) Compuestos de azabencimidazol como inhibidores de pde4 isoenzimas para el tratamiento del snc y otros trastornos
MX2016011160A (es) Tratamiento de afecciones asociadas con la hiperinsulinemia.
CR20150325A (es) Compuestos trcíclicos para inhibir el canal cftr
AR095097A1 (es) Compuestos de fenoxietoxi
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CO2018005064A2 (es) Bloqueador del canal de sodio
MX2019002369A (es) Compuestos para el tratamiento de enfermedades asociadas con una disfuncion mitocondrial.
ECSP18009366A (es) Antagonistas del receptor de cgrp
DOP2019000021A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
CO2019007836A2 (es) Derivados de pirrolotriazina como inhibidor de cinasas
AR110770A1 (es) Moduladores del canal de potasio
CL2017002651A1 (es) Derivados de aminohidrotiazina fusionados con tetrahidrofurano los cuales son útiles en el tratamiento de la enfermedad de alzheimer
MX2018007796A (es) Compuestos de fenilimidazol.
AR115865A2 (es) Compuestos terapéuticos
EA201692531A1 (ru) Способы лечения инфекций